ICD9

Body Mass Index (BMI)

These are the PRIMED Harmonization instructions for body mass index (BMI). 

Overall procedure
1. Extract trait measurements using measurement codes and calculations
2. Convert measurement units to expected units, if necessary
3. Apply measurement exclusion criteria, other than statistical outliers
4. Remove statistical outliers
5. Compute a single value per individual for inclusion in analysis
6. Calculate counts of flagged individuals

Owner Phenotyping Groups: 
View Phenotyping Groups: 
Final

Breast Cancer

These are the PRIMED Harmonization instructions for breast cancer (BC). We are using the breast cancer definition used by the eMERGE program, with some slight modifications. Follow this document for implementation.
Modifications:
We will only include cis females in the analyses
The standard definition requires controls be age 18+. If the age distribution of cases within a study is much older (e.g. 30+), then studies may filter controls based on age >= the minimum age of identified cases

Owner Phenotyping Groups: 
View Phenotyping Groups: 
Final

Computable Phenotypes for Identifying Patients with Lung and Gastroenteropancreatic Neuroendocrine Tumors in PCORnet

This phenotype specification supports the identification of patients with lung and gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) for the Neuroendocrine Tumors- Patient-Reported Outcomes Study (NET-PRO) - a multi-site, patient-centered outcomes research initiative (PCORI) funded study (RD-2020C2-20329) conducted within PCORnet.

Owner Phenotyping Groups: 
View Phenotyping Groups: 
Final

Coronary Heart Disease (CHD)

Algorithm for coronary heart disease (aka coronary artery disease) based on research done by the eMERGE Network. Cases are ascertained by either two ocurrences of diagnostic codes or one ocurrence of a procedural code. Defined as individuals with no diagnostic or procedural codes recorded. All ICD-9 and ICD-10 codes are labeled as diagnostic or procedural in the attached excel file.

Final

Febrile Neutropenia (Pediatric)

Background: Febrile neutropenia (FN) is a serious complication of myelosuppressive chemotherapy, defined by fever occurring in the context of neutropenia. Prompt recognition and treatment are essential to reduce morbidity and mortality. This algorithm focuses on "high-risk" FN as defined in the ‘Early versus Late Stopping of Antibiotics in high-risk FN’ (ELSA-FN)  randomised control trial as expected absolute neutrophil count (ANC) <500 cells/mm3 for ≥7 days.

Owner Phenotyping Groups: 
View Phenotyping Groups: 
Final

Lipids (HDL-C, LDL-C, TG)

This document describes the PRIMED Harmonization algorithms for HDL-C, LDL-C, and TG.
• High density lipoprotein (HDL-C)
• Triglycerides (TG):
o Non-fasting
• Low-density lipoprotein (LDL-C):
o Unadjusted non-fasting
o Adjusted non-fasting
Overall procedure
1. Extract trait measurements using measurement codes and calculations
2. Convert measurement units to expected units, if necessary
3. Apply measurement exclusion criteria
4. Prepare measurements for analysis

Owner Phenotyping Groups: 
View Phenotyping Groups: 
Final

Prostate Cancer

We are using the prostate cancer definition used by the eMERGE program, with a slight modification to the control definition (prostate_cancer_status_emerge_mod_1). You can review the eMERGE documentation for reference, but please follow this document for implementation.
Modifications:
Combine “Control A” and “Control B” groups from the provided schematic figure into a single control group for analysis
Controls should be filtered based on age >= the minimum age of identified cases to the age distributions of cases and controls are comparable within each study

Owner Phenotyping Groups: 
View Phenotyping Groups: 
Final

SLE (Systemic Lupus Erythematosus) using SLICC (Systemic Lupus Internation Collaborating Clinics) Criteria

Systemic Lupus Erythematosus (SLE) is a chronic, systemic autoimmune disease that can affect many parts of the body including skin, lungs, brain, heart, kidneys, joints, and blood vessels. SLE presentation can vary significantly between patients. Because of this, it can be challenging to identify a patient as having SLE. Between 300,000 and 2,000,000 people in the US are estimated to have SLE. Determination of an exact number of people affected is challenging as the disease is difficult to identify given the diverse presentations and the length of time it may take for symptoms to appear.

Owner Phenotyping Groups: 
View Phenotyping Groups: 
Final

Pages